Algorae Pharmaceuticals Ltd (Algorae Pharmaceuticals) is a biotechnology company that focus on discovery, development and commercialization of novel therapeutics for improving the wellbeing of people with debilitating conditions such as cardiovascular disease, Parkinson’s disease and dementia. The company operates through one reportable segment which includes the research and development into living cell technologies, predominantly in New Zealand. The company is also developing its technology platform AlgoraeOS. AlgoraeOS stands as its exclusive drug discovery platform, crafted through collaboration with the esteemed University of New South Wales (UNSW), recognized among the world's top 20 universities.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company focuses on R&D to discover, develop and commercialize treatments that use the regenerative healing properties of naturally occurring cells. It discovers the products through preclinical and early clinical development. The company is engaged in several R&D initiatives, including the development of AlgoraeOS, an AI-enabled drug discovery platform in partnership with the University of New South Wales (UNSW). The platform aims to leverage artificial intelligence and big data analytics to enhance drug discovery and development processes. The company is also working on AI-116, a combination drug candidate for dementia, AI-168 for cardiovascular disease, and NTCELL for Parkinson’s disease, each in collaboration with various research partners. In FY2024, the company spent AUD0.7 million on its R&D activities.